StockIQpro
NASDAQ:FDMT

4D Molecular Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

4D Molecular Therapeutics, Inc.'s revenue grew 230194.6% in fiscal 2025 to $85.2M while operating margin rose to −187.2%, its highest in 7 years. Free cash flow was −$109.6M, −128.6% of revenue, and the diluted share count rose 7.4%.Summary generated from 4D Molecular Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 18, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$85.2M
Revenue growth+230194.6%
Revenue, 5-yr CAGR+44.3%
Gross marginn/a
Operating margin−187.2%
Net margin−164.4%
ROICn/a
Return on equity−27.6%
Debt / equityn/a
Free cash flow−$109.6M
FCF margin−128.6%
Share count change+7.4%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue18321085
Operating income−71−110−113−188−160
Net income−71−107−101−161−140
Free cash flow−78−98−79−138−110

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)